The Last of The Bubble(s)

‘Idol’ Worship

If Artificial Intelligence, really is the last of the bubble(s), isn’t it appropriate we culminate in a market top of the ages, with the desire (and delusion) that we can be like God.

Let’s ask ‘AI’ how to get rid of spike protein … see what it says.

We’re around mid-day; the SOXX, is raging a bull/bear battle inside the range of yesterday’s session.

Tuesday’s session was not able to post a new high or low. With that said, the Fibonacci count from the last update remains intact.

Semiconductor SOXX, Daily

The chart shows upside pressure (volume) is dissipating.

As of this post, the MACD (not shown) is flat, waiting to tick lower; not yet confirming the bearish divergence.

A penetration of the prior session low, SOXX 524.11, would give a classical analysis sell signal (not advice, not a recommendation).

Tomorow’s TSM Earnings

Anything can happen.

SOXX, could spike higher to the previously identified 550- 560, area.

Or, we could have an immediate ‘sell the news’ event.

Either way, it’s up to the speculator/trader to decide for himself whether to take action, or not.

Biotech Short

Separately, the biotech short via LABD, has been exited with a – 7.9%, loss. So, there’s that.

On to the next trade (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

BridgeBio … Buy or Sell ?

Or … Just Another ‘Pump & Dump

Seems like anything related to the heart is all the rage these days.

Protein‘, Anyone?

So, it is with BridgeBiopharma (BBIO), currently the number three in market cap on the S&P biotech Index, SPBIO.

The daily chart shows the extent of the day’s move.

BridgeBiopharma (BBIO), Daily

Note that price action did NOT gap above resistance but pushed up to that area during the session; backing off (slightly) before the close.

Correspondingly, the leveraged inverse fund LABD had a rough day in the early session.

However, that down move was already starting to erode before the close.

Biotech Leveraged Inverse LABD, Daily

The blue arrow shows price action closed well off the lows (blue line).

Tomorrow, there are a number of data releases scheduled, link here before the open, then during the early session.

Expectations

While still maintaining a short position via LABD (not advice, not a recommendation), the expectation is BBIO, has the garden variety pump-and-dump.

We’ve all seen this movie before … right?

That is, completion of a ‘trial’ is a long way from ‘approval’ and then manufacturing start-up.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Fibonacci, Force and Biotech

Waiting For The ‘Event Horizon’

We’re going to start first, with this link, presenting the on-going fundamentals of the sector.

For those of us literally pulling their hair out, wondering if the dam is ever going to break, we have this link.

‘We’ve just poisoned 5-Billion people …’

Note: The dam break is the ‘event horizon’ where everyone collectively wakes-up. Once that happens, the ‘conspiracy’ has been proven as undeniable fact.

Biotech SPBIO, may or may not have an absolute direct connection with the aforementioned links but it’s the ‘baby with the bathwater’ response that’s expected.

Adding to that, big players in this sector have no P/E

The top-ten weightings keep changing, but the last time it was checked, none in the top-ten, had a P/E.

Since we’re working the short side, it’s the leveraged inverse fund LABD that’s of interest.

Biotech Leveraged Inverse LABD, Daily

Note the near perfect Fibonacci time correlation.

As of today’s close, price action on the LABD has got itself into a Wyckoff ‘spring position’ having decisively penetrated support (blue line), shown below.

That spring set-up has been accomplished on weak down-thrust when compared to the prior move lower.

We have a high probability of upside reversal, down for SPBIO (not advice, not a recommendation).

Positioning

Stated in the prior update, we’re short this sector (long LABD) and now have Hard Stop @ LABD 13.27 (not advice, not a recommendation).

Update: 7/13/23, 2:51 p.m. EST

LABD price action pushed to 13.26, just 0.01, below the above listed stop and is now moving higher.

Trade has been maintained (not advice, not a recommendation)

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

SOXX … The ‘AI’ Wedge Higher

Last Gasp Before August 23rd?

The SOXX chart pattern (below), is telling us we’re likely in a case of …’buy the rumor, sell the news’.

Yesterday’s action may have negated any immediate reversal downward.

Now, it looks like we’re going into a terminating wedge targeting SOXX higher to approximately 550 – 560 (not advice, not a recommendation).

Of course, anything can happen.

Semiconductor SOXX, Daily

Note, the potential for a bearish MACD divergence if SOXX moves to new highs.

If we thought there was hysteria now, just think what’s it’s going to be like if SOXX breaks to the upside.

Party, like it’s 1999

Then, Biotech SPBIO

Meanwhile back at the ranch, with about a half-hour to go before the regular session, biotech leveraged inverse LABD, is hovering at yesterday’s lows.

Biotech SPBIO, Leveraged Inverse LABD, Daily

Support (blue line) has been penetrated.

Price action has stopped dead … thus far.

This sector has been the downside leader (LABD, higher) in the past so, we’ll see if that’s happening now.

The ‘Life Insurance’ Correlation

There appears to be correlation with potential downside reversal in biotech and possible downside reversal in the life-insurance sector.

We’ll discuss that in another update.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Is Biotech (Short) Back?

First, The SOXX Housekeeping

Biotech Sector SPBIO ($SPSIBI) has got itself into a Wyckoff Up-Thrust (reversal) condition but first, we’ll update the SOXS trade.

A discretionary exit was made during this session at SOXS 10.10, for just over 1% profit (not advice, not a recommendation).

The trade was in the green and not going to be allowed to go red … a simple, but difficult to execute, trading rule.

We’re still in a bubble. That has not changed. So, it’s being watched closely.

Meanwhile, biotech SPBIO ($SPSIBI) reversed on June 14th and has been edging lower ever since. Today, we have what looks to be an up-thrust condition.

Price action has penetrated previous resistance and stalled (thus far).

Since our interest is to short the sector, we’ll go straight to the leveraged inverse fund LABD.

Biotech SPBIO, Leveraged Inverse LABD, Hourly

With about an hour before the close, price action’s penetrated support and has slowed significantly.

Positioning:

LABD entry @ 13.8766; Soft-Stop and Hard-Stop might be at the lows for the day (not advice, not a recommendation). More on that, later.

Fundamentals

The drivers for potential downside continue to grow.

Scenes like this have now entrenched themselves into the public arena.

As stated, many times (in the opinion of this author), these events are the primary driving force for all market activity on a go forward basis.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … The ‘Short’ List

A Long List, At That

The prior analysis of biotech SPBIO, had expectations for price action to rise into the 6,400 area: the location of the 200-Day Moving Average.

It did that, and more …

Back in late April, SPBIO, was in a Fibonacci time sequence. Shown below, that time structure may still be intact.

But First … The List

Note: This is not “The List“, as has been compiled (still on-going), covering the horrors of this sector but rather a list of reasons why SPBIO, is likely to head lower from here.

Here it is, not in any particular order:

Price action has reached a Fibonacci 76.4%, level

From the March 24th low, price action has retraced upward in an ‘a-b-c’ corrective move, with wave ‘a’ distance equal to wave ‘c’. Note: Equal distance ‘a’ and ‘c’, on a print basis.

At the last session, as the action pushed to a new daily high, there was ‘evidence of a struggle’ during the session to either reverse lower or move higher. Action was undecided and closed slightly below the open.

Looking at the first chart below, the daily close for the past three-years has the trend decidedly down; this sector is the weakest of all the major indices.

On the chart below, there’s a series of lower highs, lower lows that have oscillated into a massive bearish wedge.

Yesterday (Wednesday) was a Fibonacci 34 days (-1), from the print lows set on March 24th. That day was also a Fibonacci 34 days (+1), from the closing low set on March 22nd. We’re still posting a Fibonacci Time correlation.

From the highs set on February 2nd, to the lows on March 24th and then to the highs set yesterday May 10th, is symmetrical; separated by a Fibonacci 8-weeks lower and then Fibonacci 8-weeks higher.

Fundamentally, this sector is a disaster. None of the top ten equities have a P/E. All are losing money.

No P/E and operating at a loss; interest rates rising, credit standards being tightened. How are these outfits going to secure more Venture Capital (or any additional funding via stock/debt) in that environment; implosion is dead-ahead (not advice, not a recommendation).

Bank failures continue … at some point (as with the rest of us) one of these banks may be the line of credit for company payroll. Not all banks went bust in The Great Depression but just enough to halt payroll for some key industries. That event helped topple the economy.

The list goes on but that’s enough to make the point.

Now, on to the charts.

Biotech SPBIO, Daily Close

Moving closer in, to show the Fibonacci retrace, the Fibonacci time and the ‘a-b-c’ structure.

As of this post (12:25 p.m., EST) price action continues its downside reversal.

Because the retrace level (76.4%) is the highest noted by Fibonacci, we can expect some amount of upward testing if there’s going to be a sustained downside.

Anything can happen. However, with the above list compiled for both technical and fundamental conditions, probabilities point lower (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Short Squeeze … Biotech

Running The Stops

It looks like we’re in a squeeze with price action screaming higher.

As shown in the last update, the LABD hard stop was @ 16.79 (not advice, not a recommendation).

With that said, the entire short position was exited at 16.7501, early in the session.

Overall gain was around 3.96%

With the housekeeping out of the way, let’s move on to the chart and see where price action’s likely to head next.

Biotech SPBIO, Daily

We’ll get right to the point and show the most likely area to clear out stops and potentially set up for the next reversal.

The moving averages have been left in the chart (not a usual practice) because that’s the focus of the crowd.

In their minds, a close above the 200-Day MA, would be bullish.

If that happens, from a Wyckoff standpoint, we could be in up-thrust (reversal) position.

Fibonacci Time

Also of note: When a Fibonacci sequence becomes obvious, that’s when it tends to fall apart or morph into some other type of sequence.

That may be happening now.

Strategy

As always, price action can and will do whatever is necessary to extract as much from both sides (bull, bear) as possible.

It may contact the 200-MA or not. It all depends on where the most stop oerders are hiding.

Slightly above the recent highs looks like a good area for those stops.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Narrow ‘Breadth’ … What It Means

Record Extreme

One report covering the historic narrowing of the market is here.

Never before seen narrow breadth: What does it mean?

It means the market’s ‘keeping up appearances’ while the foundation’s been removed.

That way, the professionals can get out the door; sell or sell-short, funnel capital to the only three tickers left (AAPL, AMZN, MSFT), while the public looks at the SPY, and says ‘Where’s the collapse?’

Let the crowd focus on the S&P … probably the most computer controlled, AI driven, Machiavellian manipulated market in the world … but hey, I’ve got my i-phone trading app and I’m going to ‘Put it to the man’.

Meanwhile, downside leader biotech, inches lower.

Biotech SPBIO, Daily

Let’s review where we are with SPBIO, with the full understanding that anything can happen.

For now, we’re heading lower (not advice, not a recommendation).

It’s obvious. Biotech’s following a Fibonacci time sequence.

Let’s pull out to the larger weekly chart and see something really scary.

Biotech SPBIO, Weekly Close

If we really are at the right side of the trading channel, it’s not looking good for the bulls.

Of course, it all makes sense.

The market’s at record breadth divergence. Banks are collapsing, Ukraine (fabricated, or not) coupled with trade wars, the consumer’s tapped-out (credit at maximum) and on it goes.

Positioning

Early this session, the short position in biotech (via LABD) was increased (not advice, not a recommendation).

The table below shows the trading (entry) activity during the on-going reversal (not advice, not a recommendation).

Hard Stop: 16.79

The notation ‘LABD-23-05’, indicates this is the fifth trading campaign (or trade series) in LABD for the year.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

‘Mum’s The Word’

No One Talks About It

It’s interesting, but then again not, how this sector (biotech, SPBIO) gets absolutely no mention in the mainstream or on YouTube.

It made all-time highs and reversed down long before the rest of the indices (except the miners); why is it not the focus of financial and technical discussions?

We’ll leave that as an open question for now and move on to the technical condition; that is, the downside pivot may be at hand.

The last update finished with this (emphasis added):

Taking it all in aggregate, we’re obviously at an extreme and either going to reverse from here or launch into a sustained continuing directional move.

Well, reversal it is.

This update will be brief, showing the current state of SPBIO (as of 11:57 a.m., EST) and the Fibonacci time correlation from the February 2nd top.

Biotech SPBIO, Daily

For the engineers out there, the ‘exactness’ (i.e., posting extremes to the day) is not important.

What is important is to recognize the structure.

That is at this point, price action’s adhering to a Fibonacci time sequence.

Good News, Bad News

The good news is, anyone short this sector (via LABD) is now green for the day (not advice, not a recommendation).

The bad news is, this market may once again be the downside leader. We’ve already done the work on projecting target areas.

If those projections come to pass, it’s going to be a very different world. At that point, this sector may actually be the topic of mainstream and YouTube discussions.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Mastering The Reversal … Biotech

At The Extreme

We’re about to find out if Biotech’s in a new bull market or at the retrace extreme, ready for reversal.

The last update gave us the big picture on the index; a massive H&S pattern, five years in the making.

A potential trendline was shown on the daily chart of inverse fund LABD. That trend was subsequently negated by price action just hours later.

Let’s look at SPBIO, more specifically, the 4-Hour Chart.

To mimic price action of leveraged inverse LABD, we’ll invert the SPBIO.

The reason for inverting, not using LABD, is that leveraged funds have a downward bias which distorts the actual data.

Biotech SPBIO, 4-Hour, Inverted

The chart highlights Point No. 1 and Point No. 2. These areas are identified as a reminder; the prior set-up and reversal was identified, to-the-day.

There’s no guarantee the same performance will be repeated, i.e., spotting the next reversal.

The chart below, shows why we’re at The Danger Point®

Wyckoff discussed a phenomenon he called ‘shortening of the thrust’. When price action’s ready to reverse, the directional thrusts become shorter.

We’ll zoom-in on the recent action to show that Friday’s session failed to post a new daily low (high for non-inverted).

Now new low, may be the reversal nuance or not … we’ll find out at the next open (not advice, not a recommendation).

Not shown on the chart, price action’s retraced a Fibonacci 50%, of the entire move from the set-up and reversal of February 2nd, and 3rd.

Summary

Taking it all in aggregate, we’re obviously at an extreme and either going to reverse from here or launch into a sustained continuing directional move.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279